nyuuzyou/wikis huggingface dataset:
Apixaban (Eliquis)

==General information==
Class/mechanism: Selective and reversible factor Xa inhibitor. By inhibiting free and clotbound factor Xa in the coagulation cascade, apixaban inhibits prothrombinase activity, the conversion of prothrombin to thrombin, and the subsequent conversion of fibrinogen to fibrin. It does not need antithrombin III to exert its antithrombotic activity.Apixaban (Eliquis) package insert Apixaban (Eliquis) package insert (locally hosted backup)Eliquis manufacturer's website
Route: PO
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias or the prescribing information.
==Reversal information==
Andexanet alfa (Andexxa) can bind, sequester, and reverse the anticoagulation effect of rivaroxaban and apixaban.
==Diseases for which it is used==
*Atrial fibrillation
*Venous thromboembolism
==Patient drug information==
*Apixaban (Eliquis) package insert
*Apixaban (Eliquis) patient drug information (UpToDate)Apixaban (Eliquis) patient drug information (UpToDate)
==History of changes in FDA indication==
*2012-12-28: Approved to reduce the risk of stroke and dangerous blood clots (systemic embolism) in patients with atrial fibrillation that is not caused by a heart valve problem.FDA approves Eliquis to reduce the risk of stroke, blood clots in patients with non-valvular atrial fibrillation (FDA.gov) (Non-hematologic indication)
*2014-03-13: Approved for the prophylaxis of deep vein thrombosis (DVT), which may lead to pulmonary embolism (PE), in patients who have undergone hip or knee replacement surgery.
*2014-08-21: Approved for the treatment of DVT and PE, and for the reduction in the risk of recurrent DVT and PE following initial therapy.
==History of changes in EMA indication==
*2011-05-18: Initial authorization
==History of changes in PMDA indication==
*2015-12-21: New additional indication and a new dosage for the treatment and prevention of the recurrence of venous thromboembolism (deep vein thrombosis and pulmonary thromboembolism).
==Also known as==
*Brand name: Eliquis
==References==
Category:Drugs
Category:Oral medications
Category:Direct oral anticoagulants
Category:Factor Xa inhibitors
Category:Venous thromboembolism medications
Category:EMA approved in 2011
Category:FDA approved in 2012
Appendiceal tumor

Back to Top
Last updated on 2024-07-23:0 regimens on this page
0 variants on this page
=Guidelines=
Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only.
==EURACAN/PSOGI==
*2020: Govaerts et al. Appendiceal tumours and pseudomyxoma peritonei: Literature review with PSOGI/EURACAN clinical practice guidelines for diagnosis and treatment EuroPMC
==French Intergroup==
*2021: Delhorme et al. Appendiceal tumors and pseudomyxoma peritonei: French Intergroup Clinical Practice Guidelines for diagnosis, treatments and follow-up (RENAPE, RENAPATH, SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, ACHBT, SFR) EuroPMC
==NCCN==
*NCCN does not currently have guidelines at this granular level; please see NCCN Guidelines - Colon Cancer.
Category:Appendiceal tumor regimens
Category:Disease-specific pages
Category:Gastrointestinal cancers
Aprepitant (Emend)

==General information==
Class/mechanism: Substance P/neurokinin 1 (NK1) receptor antagonist. Aprepitant is able to cross the blood-brain barrier and blocks substance P activation of tachykinin family neurokinin 1 (NK1) receptors, which reduces the incidence of acute and delayed emesis.Aprepitant (Emend) package insert Aprepitant (Emend) package insert (locally hosted backup)Emend manufacturer's website
Route: PO/IV
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias or the prescribing information.
==Patient drug information==
*Brief patient counseling information can be found in the Aprepitant (Emend) package insert
*Aprepitant (Emend) patient drug information (UpToDate)Aprepitant (Emend) patient drug information (UpToDate)
==History of changes in FDA indication==
*2003-03-26: Approved for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy, including high-dose cisplatin.
*2005-10-28: Approved for prevention of nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy.
*2006-06-30: Approved for the prevention of postoperative nausea and vomiting.
==History of changes in EMA indication==
*2003-11-11: Initial authorization
==Also known as==
*Code name: MK-0869
*Brand names: Aponvie, Cinvanti, Emend, Emend Trifold
==References==
Category:Drugs
Category:Oral medications
Category:Intravenous medications
Category:Emesis prevention
Category:Neurokinin 1 (NK1) antagonists
Category:EMA approved in 2003
Category:FDA approved in 2003
Argatroban (Acova)

==General information==
Class/mechanism: Direct thrombin inhibitor, binds reversibly to free and clot-associated thrombin and inhibits its effects of catalyzing the formation of fibrin from fibrinogen, platelet aggregation, activation of protein C, and activation of coagulation factors V, VIII, and XIII.Argatroban package insert Argatroban package insert (locally hosted backup)Argatroban manufacturer's website
Route: IV
Extravasation: no information
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, UpToDate Lexidrug, Medscape, or the prescribing information.
==Patient drug information==
*Brief patient counseling information can be found in the Argatroban package insert
*Argatroban patient drug information (UpToDate)Argatroban patient drug information (UpToDate)
==Also known as==
*Brand names: Acova, Exembol, Novastan
==References==
Category:Drugs
Category:Intravenous medications
Category:Anticoagulants
Category:Direct thrombin inhibitors
Category:Heparin-induced thrombocytopenia medications
Category:Venous thromboembolism medications
Category:FDA approved in 2000
Arsenic trioxide (Trisenox)

==General information==
Class/mechanism: Causes damage or degradation of PML-RAR alpha fusion protein, causes apoptosis-type changes in NB4 human promyelocytic leukemia cells in vitro.Arsenic trioxide (Trisenox) package insert Arsenic trioxide (Trisenox) package insert (locally hosted backup)Trisenox manufacturer's website
Route: IV
Extravasation: irritant
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, UpToDate Lexidrug, Medscape, or the prescribing information.
==Diseases for which it is used==
*Acute promyelocytic leukemia
*Mantle cell lymphoma
==Patient drug information==
*Arsenic trioxide (Trisenox) package insert
*Arsenic trioxide (Trisenox) patient drug information (Chemocare)Arsenic trioxide (Trisenox) patient drug information (Chemocare)
*Arsenic trioxide (Trisenox) patient drug information (UpToDate)Arsenic trioxide (Trisenox) patient drug information (UpToDate)
==History of changes in FDA indication==
*2000-09-25: Initial FDA approval for induction of remission and consolidation in patients with acute promyelocytic leukemia (APL) who are refractory to, or have relapsed from, retinoid and anthracycline chemotherapy, and whose APL is characterized by the presence of the t(15;17) translocation or PML/RAR-alpha gene expression. (Based on PLRXAS01)
*2018-01-12: Approved in combination with tretinoin for treatment of adults with newly-diagnosed low-risk acute promyelocytic leukemia (APL) whose APL is characterized by the presence of the t(15;17) translocation or PML/RAR-alpha gene expression. (Based on GIMEMA/DSIL APL0406)
==History of changes in EMA indication==
*2002-03-05: Initial authorization (Based on PLRXAS01 & 97-66)
*2016-11-14: Extension of Indication to include induction of remission, and consolidation in adult patients with newly diagnosed low-to-intermediate risk acute promyelocytic leukaemia (APL) (white blood cell count, ≤ 10 x 103/μl) in combination with all trans retinoic acid (ATRA), characterised by the presence of the t(15;17) translocation and/or the presence of the Pro-Myelocytic Leukaemia/Retinoic-AcidReceptor-alpha (PML/RAR-alpha) gene.
==Also known as==
*Generic name: Arsenic (III) Oxide 
*Brand names: Arsenol, Arsenox, Arsitri, Leusenox, Trisenox
==References==
Category:Drugs
Category:Intravenous medications
Category:Mutation-specific medications
Category:Arsenic compound
Category:Targeted therapeutic
Category:Acute promyelocytic leukemia medications
Category:Mantle cell lymphoma medications
Category:FDA approved in 2000
Category:EMA approved in 2002
Category:WHO Essential Cancer Medicine
Asciminib (Scemblix)

==Mechanism of action==
From the NCI Drug Dictionary: An orally bioavailable, allosteric Bcr-Abl tyrosine kinase inhibitor with potential antineoplastic activity. Designed to overcome resistance, asciminib binds to the Abl portion of the Bcr-Abl fusion protein at a location that is distinct from the ATP-binding domain, and is a so-called STAMP (Specifically Targeting the ABL Myristoyl Pocket) inhibitor. This binding results in the inhibition of Bcr-Abl-mediated proliferation and enhanced apoptosis of Philadelphia chromosome-positive (Ph+) hematological malignancies.
==Diseases for which it is used==
*Chronic myeloid leukemia
==History of changes in FDA indication==
*2021-10-29: Granted accelerated approval for patients with Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase (CP), previously treated with two or more tyrosine kinase inhibitors (TKIs). (Based on ASCEMBL)
**2022-10-12: Converted to regular approval.
*2021-10-29: Approved for adult patients with Ph+ CML in CP with the T315I mutation. (Based on CABL001X2101)
*2024-10-29: Granted accelerated approval for adult patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase (CP). (Based on ASC4FIRST)
==History of changes in EMA indication==
*2022-08-25: Initial authorization as Scemblix. Scemblix is indicated for the treatment of adult patients with Philadelphia chromosome-positive chronic myeloid leukaemia in chronic phase (Ph+ CML-CP) previously treated with two or more tyrosine kinase inhibitors. (Based on ASCEMBL & CABL001X2101)
==History of changes in Health Canada indication==
*2022-06-22: Initial notice of compliance
==History of changes in PMDA indication==
*2022-03-28: Newly indicated for the treatment of chronic myelogenous leukemia with resistance or intolerance to prior drug therapies.
==Also known as==
*Code name: ABL-001
*Brand name: Scemblix
Category:Drugs
Category:Oral medications
Category:STAMP inhibitors
Category:Chronic myeloid leukemia medications
Category:FDA approved in 2021
Category:EMA approved in 2022
Category:Health Canada approved in 2022
Category:PMDA approved in 2022
Asparaginase (Elspar)

This medication was discontinued by the manufacturer in December 2012, and is now essentially out of stock. Alternatives include Pegaspargase (Oncaspar) or Asparaginase Erwinia chrysanthemi (Erwinaze).
==General information==
Class/mechanism: Depletes plasma asparagine, selectively killing leukemic cells which are unable to synthesize asparagine due to a lack of asparagine synthetase.Asparaginase (Elspar) package insert Asparaginase (Elspar) package insert (locally hosted backup)
Route: IV, IM
Extravasation: neutral
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, UpToDate Lexidrug, Medscape, or the prescribing information.
==Diseases for which it is used==
*B-cell acute lymphoblastic leukemia
*Extranodal NK- and T-cell lymphoma, nasal type
*NK- and T-cell lymphoma
*T-cell acute lymphoblastic leukemia
==Patient drug information==
*Asparaginase (Elspar) patient drug information (Chemocare)Asparaginase (Elspar) patient drug information (Chemocare)
*Asparaginase (Elspar) patient drug information (UpToDate)Asparaginase (Elspar) patient drug information (UpToDate)
==History of changes in FDA indication==
*1978-01-10: Initial approval for acute lymphocytic leukemia. (Based on CCG 101/143)
*2002-08-01 (oldest label available at Drugs @ FDA): indicated in the therapy of patients with acute lymphocytic leukemia. This agent is useful primarily in combination with other chemotherapeutic agents in the induction of remissions of the disease in pediatric patients. ELSPAR should not be used as the sole induction agent unless combination therapy is deemed inappropriate. ELSPAR is not recommended for maintenance therapy.
==Also known as==
*Generic names: colaspase, crisantaspase, L Asparaginase, L-ASP
*Brand names: Asparaginasa, Chephacardin, Colaspase, Crasnitin, Elspar, Engenase, Kidrolase, Laspar, L Asparaginasa, L Asparaginasum, L-Asperone, L-Ginase, Leucoginase, Leunase, Onconase, Paronal, Spectrila
==References==
Category:Drugs
Category:Intravenous medications
Category:Intramuscular medications
Category:Subcutaneous medications
Category:Neutral
Category:Asparagine-specific enzymes
Category:B-cell acute lymphoblastic leukemia medications
Category:Extranodal NK- and T-cell lymphoma, nasal type medications
Category:NK- and T-cell lymphoma medications
Category:T-cell acute lymphoblastic leukemia medications
Category:FDA approved in 1978
Category:Discontinued drugs
Category:WHO Essential Cancer Medicine
Asparaginase Erwinia chrysanthemi (Erwinaze)

==General information==
Class/mechanism: Depletes plasma asparagine by catalyzing the deamidation of asparagine to
aspartic acid and ammonia, selectively killing leukemic cells which are unable to synthesize asparagine due to a lack of asparagine synthetase.Asparaginase Erwinia chrysanthemi (Erwinaze) package insert Asparaginase Erwinia chrysanthemi (Erwinaze) package insert (locally hosted backup)Erwinaze manufacturer's website
Route: IM
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, UpToDate Lexidrug, Medscape, or the prescribing information.
==Diseases for which it is used==
*B-cell acute lymphoblastic leukemia
*Extranodal NK- and T-cell lymphoma, nasal type
*NK- and T-cell lymphoma
*T-cell acute lymphoblastic leukemia
==Patient drug information==
*Asparaginase patient drug information (Chemocare) — this is for Asparaginase (Elspar), not ErwinazeAsparaginase Erwinia chrysanthemi (Erwinaze) patient drug information (Chemocare)
*Brief patient counseling information can be found on the bottom of page 2 of the package insert
*Asparaginase Erwinia chrysanthemi (Erwinaze) patient drug information (UpToDate)Asparaginase Erwinia chrysanthemi (Erwinaze) patient drug information (UpToDate)
==History of changes in FDA indication==
* 2011-11-18: Initial FDA approval as a component of a multi-agent chemotherapeutic regimen for the treatment of patients with acute lymphoblastic leukemia (ALL) who have developed hypersensitivity to E. coli-derived asparaginase. (Based on COG AALL07P2)
==History of changes in PMDA indication==
*2016-12-19: Initial approval for the treatment of acute leukemia (including blast crisis of chronic leukemia) and malignant lymphoma (only for patients who experienced hypersensitivity to L-asparaginase preparations).
==Also known as==
*Generic names: crisantaspasum, crisantaspase, Erwinia L-asparginase, krisantaspaasi, krisantaspas
*Brand names: Erwinase, Erwinaze
==References==
#COG AALL07P2: Salzer WL, Asselin B, Supko JG, Devidas M, Kaiser NA, Plourde P, Winick NJ, Reaman GH, Raetz E, Carroll WL, Hunger SP. Erwinia asparaginase achieves therapeutic activity after pegaspargase allergy: a report from the Children's Oncology Group. Blood. 2013 Jul 25;122(4):507-14. Epub 2013 Jun 5. link to original article link to PMC article EuroPMC NCT00537030
Category:Drugs
Category:Intramuscular medications
Category:Asparagine-specific enzymes
Category:B-cell acute lymphoblastic leukemia medications
Category:Extranodal NK- and T-cell lymphoma, nasal type medications
Category:NK- and T-cell lymphoma medications
Category:T-cell acute lymphoblastic leukemia medications
Category:FDA approved in 2011
Category:PMDA approved in 2016
Asparaginase erwinia chrysanthemi-rywn (Rylaze)

Note: this is a recombinant product which is essentially identical to Asparaginase Erwinia chrysanthemi (Erwinaze). It is not a biosimilar.
==General information==
Class/mechanism: Depletes plasma asparagine by catalyzing the deamidation of asparagine to
aspartic acid and ammonia, selectively killing leukemic cells which are unable to synthesize asparagine due to a lack of asparagine synthetase.
Route: IM
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, UpToDate Lexidrug, Medscape, or the prescribing information.
==Diseases for which it is used==
*B-cell acute lymphoblastic leukemia
*T-cell acute lymphoblastic leukemia
==History of changes in FDA indication==
* 2021-06-30: Approved as a component of a multi-agent chemotherapeutic regimen for the treatment of acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma (LBL) in adult and pediatric patients 1 month or older who have developed hypersensitivity to E. coli-derived asparaginase. (Based on COG AALL1931)
* 2022-11-18: Approved a new Monday-Wednesday-Friday dosing regimen. Under the new regimen, patients should receive 25 mg/m2 intramuscularly on Monday and Wednesday mornings, and 50 mg/m2 intramuscularly on Friday afternoon. (Based on COG AALL1931)
==History of changes in EMA indication==
*2023-09-22: Granted marketing authorization as Enrylaze. Enrylaze is indicated as a component of a multi-agent chemotherapeutic regimen for the treatment of acute lymphoblastic leukaemia (ALL) and lymphoblastic lymphoma (LBL) in adult and paediatric patients (1 month and older) who developed hypersensitivity or silent inactivation to E. coli-derived asparaginase. (Based on COG AALL1931)
==Also known as==
*Code name: JZP-458
*Generic names: recombinant crisantaspasum, recombinant crisantaspase, recombinant Erwinia L-asparginase, recombinant krisantaspaasi, recombinant krisantaspas
*Brand names: Enrylaze, Rylaze
==References==
#COG AALL1931: Maese L, Loh ML, Choi MR, Lin T, Aoki E, Zanette M, Agarwal S, Iannone R, Silverman JA, Silverman LB, Raetz EA, Rau RE. Recombinant Erwinia asparaginase (JZP458) in acute lymphoblastic leukemia: results from the phase 2/3 AALL1931 study. Blood. 2023 Feb 16;141(7):704-712. link to original article link to PMC article EuroPMC NCT04145531
Category:Drugs
Category:Intramuscular medications
Category:Recombinant medications
Category:Asparagine-specific enzymes
Category:B-cell acute lymphoblastic leukemia medications
Category:T-cell acute lymphoblastic leukemia medications
Category:FDA approved in 2021
Category:EMA approved in 2023
Aspirin and dipyridamole (Aggrenox)

From the FDA label: A combination antiplatelet agent. Each hard gelatin capsule contains 200 mg of dipyridamole in an extended-release form and 25 mg of aspirin, as an immediate-release sugar-coated tablet.
==Also known as==
*Brand name: Aggrenox
Category:Drugs
Category:Combination drugs
Category:Oral medications
Category:COX-1 inhibitors
Category:PDE inhibitors
Category:Antipyretics
Category:FDA approved in 1999
Atezolizumab and hyaluronidase (Tecentriq Hybreza)

==General information==
Class/mechanism: PD-L1 antibody. Atezolizumab targets PD-L1 (programmed cell death-1 ligand 1) which is expressed on tumor cells and tumor-infiltrating immune cells, preventing it from binding to PD-1 and B7.1 on T-cells. By interfering with the binding of PD-L1 to T-cell receptors, it can cause upregulation of the anti-tumor immune response.
Route: SC
==Toxicity management==
*Immunotherapy toxicity management
==Diseases for which it is established==
See Atezolizumab (Tecentriq)
==History of changes in FDA indication==
*2024-09-12: Initial approval for all the adult indications as the intravenous formulation of atezolizumab. (Based on IMscin001)
==Also known as==
*Generic name: atezolizumab and hyaluronidase-tqjs
*Brand name: Tecentriq Hybreza
Category:Drugs
Category:Subcutaneous medications
Category:Anti-PD-L1 antibodies
Category:FDA approved in 2024
Atovaquone (Mepron)

==General information==
Class/mechanism: Antiprotozoal, antimicrobial. Hydroxy-1,4-naphthoquinone, analog of ubiquinone, with antipneumocystis activity. Exact mechanism unclear, but may involve inhibition of the electron transport chain in mitochondria and downstream inhibition of nucleic acid and ATP synthesis.Atovaquone (Mepron) package insert Atovaquone (Mepron) package insert (locally hosted backup)
Route: PO (typically as liquid suspension)
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, UpToDate Lexidrug, Medscape, or the prescribing information.
==Diseases for which it is used==
No known antineoplastic properties.
==Patient drug information==
*Atovaquone (Mepron) patient drug information (UpToDate)Atovaquone (Mepron) patient drug information (UpToDate)
==Also known as==
*Brand name: Mepron
==References==
Category:Drugs
Category:Oral medications
Category:PCP prophylaxis
Category:FDA approved in 1992
Aumolertinib (Ameile)

==General information==
Class/mechanism: Third generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI).
Route: PO
Extravasation: n/a
==Diseases for which it is used==
*Non-small cell lung cancer, EGFR-mutated
==Also known as==
*Code name: HS-10296
*Generic name: almonertinib
*Brand name: Ameile
==References==
Category:Drugs
Category:Oral medications
Category:EGFR inhibitors
Category:Non-small cell lung cancer medications
Category:NMPA approved drugs